

## **MEETING ABSTRACT**

**Open Access** 

## Prospective observation of breast/ovarian cancer risk in BRCA1 carriers depending on serum selenium level optimized with diet

J Lubiński<sup>\*</sup>, T Huzarski, A Jakubowska, J Gronwald, K Jaworska, M Muszyńska, G Sukiennicki, K Durda, C Cybulski, T Dębniak, A Tołoczko, O Oszurek, P Serrano-Fernandez, R Scott, S Narod

From Annual Conference on Hereditary Cancers 2010 Szczecin, Poland. 10-11 December 2010

The aim of the study is to observe prospectively the possibility of lowering the cancer risk among BRCA1 carriers by optimizing selenium concentration in diet/ organism. Results of studies performed in several centres, particularly of our own search, are strongly indicating on potential of decreasing breast/ovarian cancer risk among carriers by optimization of selenium concentration in the body. Studies will be performed on group of 1500 BRCA1 carriers. Cohort will be recruited during the first 6 months of the project. Mean length of follow-up will be 3 yrs. From all females serum will be collected for selenium analysesat the beginning and, then, every 6 months. Participants will receive the list of products with selenium concentration estimated according to literature data and, additionally, information about e-store (http:// www.dietaantyrakowa.pl) specialized in distribution of food products with defined amount of selenium. Information on optimal selenium concentration according to existing data will be provided also. It is expected that among ~750 carriers following recommended diet changes 38 cancers will be diagnosed and among the others ~750-60. The difference between groups will be statistically significant with p=0.0278. If necessary, investigation will be extended.

Published: 12 January 2012

Cite this article as: Lubiński *et al.*: Prospective observation of breast/ ovarian cancer risk in BRCA1 carriers depending on serum selenium level optimized with diet. *Hereditary Cancer in Clinical Practice* 2012 10 (Suppl 1):A11.

## Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit



<sup>\*</sup> Correspondence: lubinski@sci.pam.szczecin.pl International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland



doi:10.1186/1897-4287-10-S1-A11